Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase 2 Study for Evaluating CNS Efficacy of Belvarafenib in Patients With BRAF-Altered Solid Tumors

NCT07688356 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07688356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07688356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase 2 Study for Evaluating CNS Efficacy of Belvarafenib in Patients With BRAF-Altered Solid Tumors
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 15, 2026
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic brain tumor, primary brain tumor